Skip to main content
Clinical Trials/NCT04023487
NCT04023487
Completed
N/A

Evaluation of a Complex Intervention for Young Adults With Diabetes: The Resilient, Empowered, Active Living-Telehealth (REAL-T) Study

University of Southern California1 site in 1 country209 target enrollmentOctober 22, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Diabetes Mellitus, Type 1
Sponsor
University of Southern California
Enrollment
209
Locations
1
Primary Endpoint
Change From Baseline to 6-months in Glycemic Control, Using Glycated Hemoglobin (HbA1C)
Status
Completed
Last Updated
last year

Overview

Brief Summary

This study will evaluate (1) the efficacy of REAL-T, a lifestyle-based telehealth intervention, in improving glycemic control (HbA1c) and psychosocial outcomes, (2) which effects are retained over a 6-month follow-up period, and (3) the mediating mechanisms responsible for the intervention's effects. Half of participants will receive REAL-T, while the other half will receive their usual care.

Detailed Description

Evaluation of a Complex Behavioral Intervention for Young Adults with Diabetes: The Resilient, Empowered, Active Living-Telehealth (REAL-T) Study will address the unmet self-management and psychosocial needs of young adults (YAs) with type 1 diabetes (T1D). We will conduct a large-scale randomized controlled trial (n=210) to compare the 6-month REAL-T intervention to usual care in improving glycemic control (A1c and continuous glucose monitor-derived measures), psychosocial well-being, and hypothesized intervention mediators. In addition, we will perform health economic analyses to determine the extent to which REAL-T is cost-effective or produces cost savings. The study's specific aims are as follows: Aim 1: Evaluate the efficacy of REAL-T in improving glycemic control and psychosocial well-being. * Hypothesis 1: Over a 6-month intervention period (including 3 and 6 month measures), YAs with T1D who receive REAL-T demonstrate improvements in glycemic control, in comparison to YAs with T1D who receive usual care. * Hypothesis 2: Over a 6-month period (including 3 and 6 month measures), YAs with T1D who receive REAL-T demonstrate gains in psychosocial well-being in comparison to YAs with T1D who receive usual care. Aim 2: Assess the post-intervention durability (at 3 and 6 months post-intervention) of REAL-T's effects on glycemic control and psychosocial well-being. * Hypothesis 1: Among YAs with T1D, improvements in glycemic control that result from REAL-T relative to usual care are maintained at 3 and 6 months post-treatment. * Hypothesis 2: Among YAs with T1D, improvements in psychosocial well-being that result from REAL-T relative to usual care are maintained at 3 and 6 months post-treatment. Aim 3: Examine mediating mechanisms of the REAL-T intervention's effects on glycemic control and psychosocial well-being through structural equation modeling (SEM). * Hypothesis 1: Improvements in diabetes self-care behaviors mediate positive intervention effects on glycemic control and psychosocial well-being. * Hypothesis 2: Improvements in self-efficacy mediate positive intervention effects on psychosocial well-being and partially mediate positive effects on diabetes self-care behaviors. * Hypothesis 3: Improvements in habit strength for diabetes self-care behaviors partially mediate positive intervention effects on the performance of diabetes self-care behaviors.

Registry
clinicaltrials.gov
Start Date
October 22, 2019
End Date
November 18, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Beth Pyatak

Associate Professor

University of Southern California

Eligibility Criteria

Inclusion Criteria

  • T1D for ≥12 months
  • A1c ≥7.5% at time of study enrollment
  • Age 18-30 yrs. at time of study enrollment
  • English or Spanish speaking
  • Resides in a state where OT clinicians are licensed, in an area where the participant has access to a local healthcare provider in the event of emergency and can complete data collection in person (when permitted) or via mailings (when required during period of social distance or due to distance from study site)
  • Participant has access to a laptop or desktop computer, either their own or loaned by the study (if geographically feasible and permitted given COVID-19 social distancing distractions)
  • Willing to participate in 6-month intervention

Exclusion Criteria

  • Currently pregnant or planning to become pregnant within the next 12 months
  • Previously received REAL intervention
  • Cognitive impairment or severe disability limiting life expectancy

Outcomes

Primary Outcomes

Change From Baseline to 6-months in Glycemic Control, Using Glycated Hemoglobin (HbA1C)

Time Frame: Assessed at Baseline and 6 months; change from baseline to 6 months reported

HbA1C is a measure of average blood glucose concentration over approximately the previous 12 weeks. HbA1C will be measured using a finger-prick test using the DCA Vantage Analyzer point-of-care system OR AccuBase A1c test with DTI Laboratories. Assessed at Baseline and 6 months; change from baseline to 6 months reported.

Secondary Outcomes

  • Change in Self-efficacy for Performing Diabetes Self-management, Using the "Diabetes Empowerment Scale - Short Form" (DES-SF)(Baseline, 3 months, 6 months, 9 months, and 12 months)
  • Change From Baseline to 6-months Post-test in Glycemia, Using Percent Time in Hyperglycemia(Assessed at Baseline and 6 months; change from baseline to 6 months reported)
  • Change From Baseline to 6-months Post-test in Diabetes-related Quality of Life, Using the "Audit of Diabetes-Dependent Quality of Life-15" (ADD-QoL-15)(Assessed at Baseline and 6 months; change from baseline to 6 months reported)
  • Change in Medication Adherence, Using the "3-item Adherence Self-report Scale" Questionnaire(Baseline, 3 months, 6 months, 9 months, and 12 months)
  • Change From Baseline to 6-months Post-test in Diabetes-related Emotional Distress, Using the "Diabetes Distress Scale" (DDS)(Assessed at Baseline and 6 months; change from baseline to 6 months reported)
  • Change in Functional Health and Well-being, Using the "SF-12v2® Health Survey"(Baseline, 6 months, and 12 months)
  • Change in Global Diabetes Self-management, Using the "Diabetes Self-Management Questionnaire-Revised" (DSMQ-R).(Baseline, 3 months, 6 months, 9 months, and 12 months)
  • Change in Autonomy of Taking Insulin and/or Checking Blood Sugar, Using the "Treatment Self-Regulation Questionnaire" (TSRQ)(Baseline, 3 months, 6 months, 9 months, and 12 months)
  • Change From Baseline to 6-months Post-test in Glycemia, Using Percent Time-in-Range(Assessed at Baseline and 6 months; change from baseline to 6 months reported)
  • Change From Baseline to 6-months Post-test in Glycemia, Using Percent Time in Hypoglycemia(Assessed at Baseline and 6 months; change from baseline to 6 months reported)
  • Change in Cost to Patients(Baseline, 3 months, 6 months, 9 months, and 12 months)
  • Change in Cost to Payor(Baseline, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, and 12 months)

Study Sites (1)

Loading locations...

Similar Trials